{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:20:14Z","timestamp":1783509614284,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Surgical resection for medulloblastoma has been a mainstay of treatment for decades due to the need for definitive diagnosis and known benefits on treatment efficacy and survival. While many pediatric neurosurgeons and neurooncologists agree that maximal safe surgical resection should be the goal of medulloblastoma surgery, actual practical application and benefits of maximal safe resection seem to vary. Early work on extent of resection provided a relatively arbitrary 1.5 cm\n                    <jats:sup>2<\/jats:sup>\n                    threshold to distinguish subtotal resection (STR) from near total resection (NTR) and demonstrated a survival benefit if the residual was\u2009\u2264\u20091.5 cm\n                    <jats:sup>2<\/jats:sup>\n                    (NTR or gross total resection (GTR)). However, recent evidence questions the validity of this threshold, with European researchers even suggesting that STR alone should not be considered a high-risk feature during adjuvant therapy planning. The question regarding extent of resection, therefore, is undeniably controversial and has become even more complex in recent years due to the seminal work done to identify medulloblastoma subgroups based on molecular characteristics. Adjuvant treatment approaches are being tailored to these molecular subgroups, and the impact of extent of resection on survival is being reconsidered within the context of subgroups. Certainly, the goal when treating children with medulloblastoma, or any form of brain cancer, should be to cure the disease while minimizing treatment-related toxicity, including surgical injury. In this article, we discuss the role of surgical resection for treating medulloblastoma and whether it is possible to maximize both surgical resection, to potentially improve survival and adjuvant treatment efficacy, while minimizing neurological morbidity.\n                  <\/jats:p>","DOI":"10.1007\/s00381-026-07355-0","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:04:58Z","timestamp":1783508698000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surgical resection in medulloblastoma: a crossroads in the molecular era"],"prefix":"10.1007","volume":"42","author":[{"given":"Joseph H.","family":"McAbee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Laird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Gajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hersh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Shimony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Aquilina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Paul","family":"Klimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"7355_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/00006123-199602000-00007","volume":"38","author":"AL Albright","year":"1996","unstructured":"Albright AL, Wisoff JH, Zeltzer PM, Boyett JM, Rorke LB, Stanley P (1996) Effects of medulloblastoma resections on outcome in children: a report from the Children\u2019s Cancer Group. Neurosurgery 38:265\u2013271. https:\/\/doi.org\/10.1097\/00006123-199602000-00007","journal-title":"Neurosurgery"},{"key":"7355_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejcped.2024.100205","volume":"5","author":"S Bailey","year":"2025","unstructured":"Bailey S, Jacobs S, Kourti M, Massimino M, Andre N, Doz F, Dufour C, Vennarini S, Padovani L, Aquilina K, Thomale U, Joshi A, Pietsch T, Avula S, Morana G, Rutkowski S, Pizer B, Clifford SC (2025) Medulloblastoma therapy: consensus treatment recommendations from SIOP-Europe and the European Reference Network. EJC Paediatr Oncol 5:1\u201318. https:\/\/doi.org\/10.1016\/j.ejcped.2024.100205","journal-title":"EJC Paediatr Oncol"},{"key":"7355_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13081898","author":"J Bonifacio-Mundaca","year":"2025","unstructured":"Bonifacio-Mundaca J, Casavilca-Zambrano S, Desterke C, Casafont I, Mata-Garrido J (2025) Deciphering medulloblastoma: epigenetic and metabolic changes driving tumorigenesis and treatment outcomes. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines13081898","journal-title":"Biomedicines"},{"key":"7355_CR4","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41591-024-03435-3","volume":"31","author":"B Brandl","year":"2025","unstructured":"Brandl B, Steiger M, Kubelt C, Rohrandt C, Zhu Z, Evers M, Wang G, Schuldt B, Afflerbach AK, Wong D, Lum A, Halldorsson S, Djirackor L, Leske H, Magadeeva S, Smicius R, Quedenau C, Schmidt NO, Schuller U, Vik-Mo EO, Proescholdt M, Riemenschneider MJ, Zadeh G, Ammerpohl O, Yip S, Synowitz M, van Bommel A, Kretzmer H, Muller FJ (2025) Rapid brain tumor classification from sparse epigenomic data. Nat Med 31:840\u2013848. https:\/\/doi.org\/10.1038\/s41591-024-03435-3","journal-title":"Nat Med"},{"key":"7355_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00401-012-1070-9","volume":"125","author":"AM Dubuc","year":"2013","unstructured":"Dubuc AM, Remke M, Korshunov A, Northcott PA, Zhan SH, Mendez-Lago M, Kool M, Jones DT, Unterberger A, Morrissy AS, Shih D, Peacock J, Ramaswamy V, Rolider A, Wang X, Witt H, Hielscher T, Hawkins C, Vibhakar R, Croul S, Rutka JT, Weiss WA, Jones SJ, Eberhart CG, Marra MA, Pfister SM, Taylor MD (2013) Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol 125:373\u2013384. https:\/\/doi.org\/10.1007\/s00401-012-1070-9","journal-title":"Acta Neuropathol"},{"key":"7355_CR6","doi-asserted-by":"publisher","DOI":"10.3171\/2025.12.PEDS25467","author":"R Dvir","year":"2026","unstructured":"Dvir R, Elhasid R, Roth J, Constantini S, Peled Y, Ospovat I, Shiran SI (2026) Pediatric metastatic medulloblastoma: upfront biopsy followed by oncological treatment without excision of the primary tumor. J Neurosurg Pediatr. https:\/\/doi.org\/10.3171\/2025.12.PEDS25467","journal-title":"J Neurosurg Pediatr"},{"key":"7355_CR7","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s00381-021-05082-2","volume":"37","author":"AE Enayet","year":"2021","unstructured":"Enayet AE, Nabil M, Rady MR, Yousef Y, Badawy E, El Beltagy MA (2021) Surgical outcome of children with medulloblastoma: a retrospective study of a 405-patient series from Children\u2019s Cancer Hospital Egypt (CCHE-57357). Childs Nerv Syst 37:1931\u20131940. https:\/\/doi.org\/10.1007\/s00381-021-05082-2","journal-title":"Childs Nerv Syst"},{"key":"7355_CR8","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/neuonc\/noae279","volume":"27","author":"M Filser","year":"2025","unstructured":"Filser M, Torrejon J, Merchadou K, Dufour C, Girard E, Bourneix C, Lemaitre E, Gharsalli T, Brillet R, Wong J, Gentien D, Rapinat A, Servant N, Vasiljevic A, Bertozzi AI, Raimbault S, Tauziede Espariat A, Lhermitte B, Faure-Conter C, Icher C, Berger C, Maurage CA, Bodet D, Meyronet D, Uro-Coste E, De Carli E, Forest F, Palenzuela G, Chotard G, Gauchotte G, Sudour H, Mansuy L, Deparis M, Tallegas M, Faisant M, Entz-Werle N, Varlet P, Leblond P, Michalak-Provost S, Proust Houdemont S, Rigau V, Doz F, Delattre O, Bourdeaut F, Ayrault O, Masliah-Planchon J (2025) Nanopore sequencing as a cutting-edge technology for medulloblastoma classification. Neuro Oncol 27:1313\u20131324. https:\/\/doi.org\/10.1093\/neuonc\/noae279","journal-title":"Neuro Oncol"},{"key":"7355_CR9","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1200\/JCO.20.01372","volume":"39","author":"A Gajjar","year":"2021","unstructured":"Gajjar A, Robinson GW, Smith KS, Lin T, Merchant TE, Chintagumpala M, Mahajan A, Su J, Bouffet E, Bartels U, Schechter T, Hassall T, Robertson T, Nicholls W, Gururangan S, Schroeder K, Sullivan M, Wheeler G, Hansford JR, Kellie SJ, McCowage G, Cohn R, Fisher MJ, Krasin MJ, Stewart CF, Broniscer A, Buchhalter I, Tatevossian RG, Orr BA, Neale G, Klimo P Jr, Boop F, Srinivasan A, Pfister SM, Gilbertson RJ, Onar-Thomas A, Ellison DW, Northcott PA (2021) Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03). J Clin Oncol 39:822\u2013835. https:\/\/doi.org\/10.1200\/JCO.20.01372","journal-title":"J Clin Oncol"},{"key":"7355_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2352-4642(20)30246-7","volume":"4","author":"RM Hill","year":"2020","unstructured":"Hill RM, Richardson S, Schwalbe EC, Hicks D, Lindsey JC, Crosier S, Rafiee G, Grabovska Y, Wharton SB, Jacques TS, Michalski A, Joshi A, Pizer B, Williamson D, Bailey S, Clifford SC (2020) Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study. Lancet Child Adolesc Health 4:865\u2013874. https:\/\/doi.org\/10.1016\/S2352-4642(20)30246-7","journal-title":"Lancet Child Adolesc Health"},{"key":"7355_CR11","doi-asserted-by":"publisher","first-page":"102469","DOI":"10.1016\/j.eclinm.2024.102469","volume":"69","author":"C Keeling","year":"2024","unstructured":"Keeling C, Davies S, Goddard J, Ramaswamy V, Schwalbe EC, Bailey S, Hicks D, Clifford SC (2024) The clinical significance of sub-total surgical resection in childhood medulloblastoma: a multi-cohort analysis of 1100 patients. EClinicalMedicine 69:102469. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102469","journal-title":"EClinicalMedicine"},{"key":"7355_CR12","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/neuonc\/noab030","volume":"23","author":"RB Khan","year":"2021","unstructured":"Khan RB, Patay Z, Klimo P, Huang J, Kumar R, Boop FA, Raches D, Conklin HM, Sharma R, Simmons A, Sadighi ZS, Onar-Thomas A, Gajjar A, Robinson GW (2021) Clinical features, neurologic recovery, and risk factors of postoperative posterior fossa syndrome and delayed recovery: a prospective study. Neuro Oncol 23:1586\u20131596. https:\/\/doi.org\/10.1093\/neuonc\/noab030","journal-title":"Neuro Oncol"},{"key":"7355_CR13","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2011.39.8719","volume":"30","author":"B Lannering","year":"2012","unstructured":"Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, Massimino M, Reddingius R, Benesch M, Carrie C, Taylor R, Gandola L, Bjork-Eriksson T, Giralt J, Oldenburger F, Pietsch T, Figarella-Branger D, Robson K, Forni M, Clifford SC, Warmuth-Metz M, von Hoff K, Faldum A, Mosseri V, Kortmann R (2012) Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 30:3187\u20133193. https:\/\/doi.org\/10.1200\/JCO.2011.39.8719","journal-title":"J Clin Oncol"},{"key":"7355_CR14","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231\u20131251. https:\/\/doi.org\/10.1093\/neuonc\/noab106","journal-title":"Neuro Oncol"},{"key":"7355_CR15","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1200\/JCO.20.02730","volume":"39","author":"JM Michalski","year":"2021","unstructured":"Michalski JM, Janss AJ, Vezina LG, Smith KS, Billups CA, Burger PC, Embry LM, Cullen PL, Hardy KK, Pomeroy SL, Bass JK, Perkins SM, Merchant TE, Colte PD, Fitzgerald TJ, Booth TN, Cherlow JM, Muraszko KM, Hadley J, Kumar R, Han Y, Tarbell NJ, Fouladi M, Pollack IF, Packer RJ, Li Y, Gajjar A, Northcott PA (2021) Children\u2019s Oncology Group Phase III trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 39:2685\u20132697. https:\/\/doi.org\/10.1200\/JCO.20.02730","journal-title":"J Clin Oncol"},{"key":"7355_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13243680","author":"N Mushtaq","year":"2023","unstructured":"Mushtaq N, Ul Ain R, Hamid SA, Bouffet E (2023) Evolution of systemic therapy in medulloblastoma including irradiation-sparing approaches. Diagnostics (Basel). https:\/\/doi.org\/10.3390\/diagnostics13243680","journal-title":"Diagnostics (Basel)"},{"key":"7355_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236077","author":"M Mynarek","year":"2021","unstructured":"Mynarek M, Milde T, Padovani L, Janssens GO, Kwiecien R, Mosseri V, Clifford SC, Doz F, Rutkowski S (2021) SIOP PNET5 MB trial: history and concept of a molecularly stratified clinical trial of risk-adapted therapies for standard-risk medulloblastoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13236077","journal-title":"Cancers (Basel)"},{"key":"7355_CR18","doi-asserted-by":"publisher","first-page":"iii1","DOI":"10.1093\/neuonc\/noac161","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom QT, Price M, Ryan K, Edelson J, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS (2022) CBTRUS statistical report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018. Neuro Oncol 24:iii1\u2013iii38. https:\/\/doi.org\/10.1093\/neuonc\/noac161","journal-title":"Neuro Oncol"},{"key":"7355_CR19","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41591-025-03562-5","volume":"31","author":"A Patel","year":"2025","unstructured":"Patel A, Gobel K, Ille S, Hinz F, Schoebe N, Bogumil H, Meyer J, Brehm M, Kardo H, Schrimpf D, Lomakin A, Ritter M, Goller P, Kerbs P, Pfeifer L, Hamelmann S, Blume C, Ippen FM, Berghaus N, Euskirchen P, Schweizer L, Hultschig C, Van Roy N, Van Dorpe J, Van der Meulen J, Loontiens S, Dedeurwaerdere F, Leske H, Halldorsson S, Fox G, Deacon S, Cahyani I, Holmes N, Wibowo S, Munro R, Martin D, Sharif A, Housley M, Goldspring R, Brandner S, Roy S, Hench J, Frank S, Unterberg A, Goidts V, Jager N, Paine S, Smith S, Herold-Mende C, Wick W, Pfister SM, Vik-Mo EO, von Deimling A, Krieg S, Jones DT, Loose M, Schlesner M, Sill M, Sahm F (2025) Prospective, multicenter validation of a platform for rapid molecular profiling of central nervous system tumors. Nat Med 31:1567\u20131577. https:\/\/doi.org\/10.1038\/s41591-025-03562-5","journal-title":"Nat Med"},{"key":"7355_CR20","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/neuros\/nyy095","volume":"84","author":"P Patel","year":"2019","unstructured":"Patel P, Wallace D, Boop FA, Vaughn B, Robinson GW, Gajjar A, Klimo P (2019) Reoperation for medulloblastoma prior to adjuvant therapy. Neurosurgery 84:1050\u20131058. https:\/\/doi.org\/10.1093\/neuros\/nyy095","journal-title":"Neurosurgery"},{"key":"7355_CR21","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00381-023-06239-x","volume":"40","author":"JS Rechberger","year":"2024","unstructured":"Rechberger JS, Power EA, DeCuypere M, Daniels DJ (2024) Evolution of neurosurgical advances and nuances in medulloblastoma therapy. Childs Nerv Syst 40:1031\u20131044. https:\/\/doi.org\/10.1007\/s00381-023-06239-x","journal-title":"Childs Nerv Syst"},{"key":"7355_CR22","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(18)30204-3","volume":"19","author":"GW Robinson","year":"2018","unstructured":"Robinson GW, Rudneva VA, Buchhalter I, Billups CA, Waszak SM, Smith KS, Bowers DC, Bendel A, Fisher PG, Partap S, Crawford JR, Hassall T, Indelicato DJ, Boop F, Klimo P, Sabin ND, Patay Z, Merchant TE, Stewart CF, Orr BA, Korbel JO, Jones DTW, Sharma T, Lichter P, Kool M, Korshunov A, Pfister SM, Gilbertson RJ, Sanders RP, Onar-Thomas A, Ellison DW, Gajjar A, Northcott PA (2018) Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncol 19:768\u2013784. https:\/\/doi.org\/10.1016\/S1470-2045(18)30204-3","journal-title":"Lancet Oncol"},{"key":"7355_CR23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/neuonc\/noae178","volume":"27","author":"EC Schwalbe","year":"2025","unstructured":"Schwalbe EC, Lindsey JC, Danilenko M, Hill RM, Crosier S, Ryan SL, Williamson D, Castle J, Hicks D, Kool M, Milde T, Korshunov A, Pfister SM, Bailey S, Clifford SC (2025) Molecular and clinical heterogeneity within MYC-family amplified medulloblastoma is associated with survival outcomes: a multicenter cohort study. Neuro Oncol 27:222\u2013236. https:\/\/doi.org\/10.1093\/neuonc\/noae178","journal-title":"Neuro Oncol"},{"key":"7355_CR24","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00401-019-02020-0","volume":"138","author":"T Sharma","year":"2019","unstructured":"Sharma T, Schwalbe EC, Williamson D, Sill M, Hovestadt V, Mynarek M, Rutkowski S, Robinson GW, Gajjar A, Cavalli F, Ramaswamy V, Taylor MD, Lindsey JC, Hill RM, Jager N, Korshunov A, Hicks D, Bailey S, Kool M, Chavez L, Northcott PA, Pfister SM, Clifford SC (2019) Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. Acta Neuropathol 138:309\u2013326. https:\/\/doi.org\/10.1007\/s00401-019-02020-0","journal-title":"Acta Neuropathol"},{"key":"7355_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf250","author":"AKS Smith","year":"2025","unstructured":"Smith AKS, Dhanda SK, Billups CA, Sioson E, Lu C, Peraza AZ, Gangwani K, Li Y, Li Q, Lin T, Michalski JM, Packer RJ, Olson JM, Leary SES, Fouladi M, Gajjar A, Zhou X, Onar-Thomas A, Northcott PA, Robinson GW (2025) An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/noaf250","journal-title":"Neuro Oncol"},{"key":"7355_CR26","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00401-011-0922-z","volume":"123","author":"MD Taylor","year":"2012","unstructured":"Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DL, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123:465\u2013472. https:\/\/doi.org\/10.1007\/s00401-011-0922-z","journal-title":"Acta Neuropathol"},{"key":"7355_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11060-018-2906-5","volume":"139","author":"EM Thompson","year":"2018","unstructured":"Thompson EM, Bramall A, Herndon JE 2nd, Taylor MD, Ramaswamy V (2018) The clinical importance of medulloblastoma extent of resection: a systematic review. J Neurooncol 139:523\u2013539. https:\/\/doi.org\/10.1007\/s11060-018-2906-5","journal-title":"J Neurooncol"},{"key":"7355_CR28","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1470-2045(15)00581-1","volume":"17","author":"EM Thompson","year":"2016","unstructured":"Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, McLendon RE, Bigner DD, Lipp ES, Perreault S, Cho YJ, Grant G, Kim SK, Lee JY, Rao AAN, Giannini C, Li KKW, Ng HK, Yao Y, Kumabe T, Tominaga T, Grajkowska WA, Perek-Polnik P, Low DCY, Seow WT, Chang KTE, Mora J, Pollack IF, Hamilton RL, Leary S, Moore AS, Ingram WJ, Hallahan AR, Jouvet A, Fevre-Montange M, Vasiljevic A, Faure-Conter C, Shofuda T, Kagawa N, Hashimoto N, Jabado N, Weil AG, Gayden T, Wataya T, Shalaby T, Grotzer M, Zitterbart K, Sterba J, Kren L, Hortobagyi T, Klekner A, Laszlo B, Pocza T, Hauser P, Schuller U, Jung S, Jang WY, French PJ, Kros JM, van Veelen MC, Massimi L, Leonard JR, Rubin JB, Vibhakar R, Chambless LB, Cooper MK, Thompson RC, Faria CC, Carvalho A, Nunes S, Pimentel J, Fan X, Muraszko KM, Lopez-Aguilar E, Lyden D, Garzia L, Shih DJH, Kijima N, Schneider C, Adamski J, Northcott PA, Kool M, Jones DTW, Chan JA, Nikolic A, Garre ML, Van Meir EG, Osuka S, Olson JJ, Jahangiri A, Castro BA, Gupta N, Weiss WA, Moxon-Emre I, Mabbott DJ, Lassaletta A, Hawkins CE, Tabori U, Drake J, Kulkarni A, Dirks P, Rutka JT, Korshunov A, Pfister SM, Packer RJ, Ramaswamy V, Taylor MD (2016) Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol 17:484\u2013495. https:\/\/doi.org\/10.1016\/S1470-2045(15)00581-1","journal-title":"Lancet Oncol"},{"key":"7355_CR29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3171\/2025.5.PEDS2593","volume":"36","author":"SM Toescu","year":"2025","unstructured":"Toescu SM, Pizer B, Gump W, Aquilina K, Avula S, Mallucci C, Parks C, Carai A, Robinson G, Aldave G, Baird L, Niazi T, Keating R, Klimo P Jr. (2025) Toward reducing the risk of cerebellar mutism syndrome: consensus statement from the Posterior Fossa Society. J Neurosurg Pediatr 36:789\u2013797. https:\/\/doi.org\/10.3171\/2025.5.PEDS2593","journal-title":"J Neurosurg Pediatr"},{"key":"7355_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3171\/2009.11.PEDS09131","volume":"5","author":"EM Wells","year":"2010","unstructured":"Wells EM, Khademian ZP, Walsh KS, Vezina G, Sposto R, Keating RF, Packer RJ (2010) Postoperative cerebellar mutism syndrome following treatment of medulloblastoma: neuroradiographic features and origin. J Neurosurg Pediatr 5:329\u2013334. https:\/\/doi.org\/10.3171\/2009.11.PEDS09131","journal-title":"J Neurosurg Pediatr"},{"key":"7355_CR31","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1200\/JCO.1999.17.3.832","volume":"17","author":"PM Zeltzer","year":"1999","unstructured":"Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, Allen JC, Stevens KR, Stanley P, Li H, Wisoff JH, Geyer JR, McGuire-Cullen P, Stehbens JA, Shurin SB, Packer RJ (1999) Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children\u2019s Cancer Group 921 randomized phase III study. J Clin Oncol 17:832\u2013845. https:\/\/doi.org\/10.1200\/JCO.1999.17.3.832","journal-title":"J Clin Oncol"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-026-07355-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00381-026-07355-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-026-07355-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:04:59Z","timestamp":1783508699000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00381-026-07355-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7355"],"URL":"https:\/\/doi.org\/10.1007\/s00381-026-07355-0","relation":{},"ISSN":["1433-0350"],"issn-type":[{"value":"1433-0350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"290"}}